Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sirolimus, quantity: 1 mg/ml - oral liquid, solution - excipient ingredients: polysorbate 80; propylene glycol; ethanol; ascorbyl palmitate; phosphatidyl choline; mono- and di- glycerides; soy fatty acids - indications as at 9 february 2004: rapamune is indicated for the prophylaxis of organ rejection in patients at mild to moderate immunological risk receiving renal transplants. therapeutic drug monitoring of sirolimus is required.

United Kingdom - Inggeris - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - aprepitant - oral capsule - 80mg

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - levetiracetam, quantity: 100 mg/ml - oral liquid, solution - excipient ingredients: maltitol solution; purified water; citric acid monohydrate; glycerol; methyl hydroxybenzoate; propylene glycol; sodium citrate dihydrate; acesulfame potassium; propyl hydroxybenzoate; ammonium glycyrrhizinate; flavour - use in epileptic patients aged 4 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation; monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy; add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme); and add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (ige).

United Kingdom - Inggeris - MHRA (Medicines & Healthcare Products Regulatory Agency)

sandoz ltd - aprepitant - oral capsule - 125mg

United Kingdom - Inggeris - MHRA (Medicines & Healthcare Products Regulatory Agency)

zentiva pharma uk ltd - aprepitant - oral capsule - 80mg

United Kingdom - Inggeris - MHRA (Medicines & Healthcare Products Regulatory Agency)

zentiva pharma uk ltd - aprepitant - oral capsule - 125mg

United Kingdom - Inggeris - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - aprepitant - oral capsule - 125mg

United Kingdom - Inggeris - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - aprepitant - oral capsule - 125mg

United Kingdom - Inggeris - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - aprepitant - oral capsule - 125mg

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - tofacitinib citrate, quantity: 1.62 mg/ml (equivalent: tofacitinib, qty 1 mg/ml) - solution - excipient ingredients: xylitol; lactic acid; sucralose; sodium benzoate; hydrochloric acid; purified water; flavour - rheumatoid arthritis (ra),xeljanz is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults who have had an inadequate response or are intolerant to methotrexate. xeljanz can be used alone or in combination with conventional synthetic disease-modifying antirheumatic drugs (dmards), including methotrexate.,psoriatic arthritis (psa),xeljanz in combination with conventional synthetic dmards is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response to a prior dmard therapy.,ulcerative colitis (uc),xeljanz is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biological therapy.,ankylosing spondylitis (as),xeljanz is indicated for the treatment of adult patients with active ankylosing spondylitis who have responded inadequately to conventional therapy.,juvenile idiopathic arthritis (jia),xeljanz is indicated for the treatment of active polyarticular course juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis, extended oligoarthritis and systemic juvenile arthritis without systemic features for six months) and juvenile psoriatic arthritis in patients 2 years of age and older, who have responded inadequately to previous therapy with dmards.